Oncolytic Herpes Simplex Virus-Based Therapies for Cancer

With the increased worldwide burden of cancer, including aggressive and resistant cancers, oncolytic virotherapy has emerged as a viable therapeutic option. Oncolytic herpes simplex virus (oHSV) can be genetically engineered to target cancer cells while sparing normal cells. This leads to the direct...

Descripción completa

Detalles Bibliográficos
Autores principales: Aldrak, Norah, Alsaab, Sarah, Algethami, Aliyah, Bhere, Deepak, Wakimoto, Hiroaki, Shah, Khalid, Alomary, Mohammad N., Zaidan, Nada
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235327/
https://www.ncbi.nlm.nih.gov/pubmed/34207386
http://dx.doi.org/10.3390/cells10061541
_version_ 1783714291157827584
author Aldrak, Norah
Alsaab, Sarah
Algethami, Aliyah
Bhere, Deepak
Wakimoto, Hiroaki
Shah, Khalid
Alomary, Mohammad N.
Zaidan, Nada
author_facet Aldrak, Norah
Alsaab, Sarah
Algethami, Aliyah
Bhere, Deepak
Wakimoto, Hiroaki
Shah, Khalid
Alomary, Mohammad N.
Zaidan, Nada
author_sort Aldrak, Norah
collection PubMed
description With the increased worldwide burden of cancer, including aggressive and resistant cancers, oncolytic virotherapy has emerged as a viable therapeutic option. Oncolytic herpes simplex virus (oHSV) can be genetically engineered to target cancer cells while sparing normal cells. This leads to the direct killing of cancer cells and the activation of the host immunity to recognize and attack the tumor. Different variants of oHSV have been developed to optimize its antitumor effects. In this review, we discuss the development of oHSV, its antitumor mechanism of action and the clinical trials that have employed oHSV variants to treat different types of tumor.
format Online
Article
Text
id pubmed-8235327
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-82353272021-06-27 Oncolytic Herpes Simplex Virus-Based Therapies for Cancer Aldrak, Norah Alsaab, Sarah Algethami, Aliyah Bhere, Deepak Wakimoto, Hiroaki Shah, Khalid Alomary, Mohammad N. Zaidan, Nada Cells Review With the increased worldwide burden of cancer, including aggressive and resistant cancers, oncolytic virotherapy has emerged as a viable therapeutic option. Oncolytic herpes simplex virus (oHSV) can be genetically engineered to target cancer cells while sparing normal cells. This leads to the direct killing of cancer cells and the activation of the host immunity to recognize and attack the tumor. Different variants of oHSV have been developed to optimize its antitumor effects. In this review, we discuss the development of oHSV, its antitumor mechanism of action and the clinical trials that have employed oHSV variants to treat different types of tumor. MDPI 2021-06-18 /pmc/articles/PMC8235327/ /pubmed/34207386 http://dx.doi.org/10.3390/cells10061541 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Aldrak, Norah
Alsaab, Sarah
Algethami, Aliyah
Bhere, Deepak
Wakimoto, Hiroaki
Shah, Khalid
Alomary, Mohammad N.
Zaidan, Nada
Oncolytic Herpes Simplex Virus-Based Therapies for Cancer
title Oncolytic Herpes Simplex Virus-Based Therapies for Cancer
title_full Oncolytic Herpes Simplex Virus-Based Therapies for Cancer
title_fullStr Oncolytic Herpes Simplex Virus-Based Therapies for Cancer
title_full_unstemmed Oncolytic Herpes Simplex Virus-Based Therapies for Cancer
title_short Oncolytic Herpes Simplex Virus-Based Therapies for Cancer
title_sort oncolytic herpes simplex virus-based therapies for cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235327/
https://www.ncbi.nlm.nih.gov/pubmed/34207386
http://dx.doi.org/10.3390/cells10061541
work_keys_str_mv AT aldraknorah oncolyticherpessimplexvirusbasedtherapiesforcancer
AT alsaabsarah oncolyticherpessimplexvirusbasedtherapiesforcancer
AT algethamialiyah oncolyticherpessimplexvirusbasedtherapiesforcancer
AT bheredeepak oncolyticherpessimplexvirusbasedtherapiesforcancer
AT wakimotohiroaki oncolyticherpessimplexvirusbasedtherapiesforcancer
AT shahkhalid oncolyticherpessimplexvirusbasedtherapiesforcancer
AT alomarymohammadn oncolyticherpessimplexvirusbasedtherapiesforcancer
AT zaidannada oncolyticherpessimplexvirusbasedtherapiesforcancer

Ejemplares similares